Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USA

Core Points - Genentech has commenced construction on its first manufacturing facility on the East Coast, located in Holly Springs, North Carolina, which will support the production of metabolic medicines, including obesity treatments [1][2] - The initial investment for this facility exceeds $700 million and is part of Roche's broader commitment of $50 billion towards US manufacturing infrastructure and R&D [2][8] - The facility is expected to create over 1,900 jobs and is strategically located in a growing biopharmaceutical hub with access to a skilled workforce and leading academic institutions [2][8] Facility Details - The new facility will cover an area of 65,000 m² and is designed to incorporate modern biomanufacturing technologies, advanced automation, and digital capabilities [3] - It is projected to be operational by 2029 and will enhance Roche's manufacturing capacity and supply chain resilience [3][4] - The facility will also allow for future expansion on the 400,000 m² lot [3] Company Background - Roche, founded in 1896, is the world's largest biotechnology company and a leader in in-vitro diagnostics, focusing on developing innovative medicines and diagnostics [5][6] - The company has a long-standing commitment to sustainability and aims to achieve net zero by 2045 [6]